SG11201808829VA - Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease - Google Patents

Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Info

Publication number
SG11201808829VA
SG11201808829VA SG11201808829VA SG11201808829VA SG11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA
Authority
SG
Singapore
Prior art keywords
international
tdp
ohio
april
pct
Prior art date
Application number
SG11201808829VA
Inventor
Xinglong Wang
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of SG11201808829VA publication Critical patent/SG11201808829VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011101111101011111101111101111011111 International Bureau 0.. .... .. ..... ..or::,,, (10) International Publication Number (43) International Publication Date WO 2017/177178 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C07K 7/00 (2006.01) C07K 19/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07K 7/06 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2017/026675 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 7 April 2017 (07.04.2017) TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/319,580 7 April 2016 (07.04.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/328,484 27 April 2016 (27.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: CASE WESTERN RESERVE UNIVER- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SITY [US/US]; 10900 Euclid Avenue, Cleveland, Ohio SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 44106 (US). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: WANG, Xinglong; 10900 Euclid Avenue, Clev- Published: eland, Ohio 44106 (US). — with international search report (Art. 21(3)) (74) Agent: SUTKUS, Richard A.; 1300 E. 9th Street, Suite before the expiration of the time limit for amending the 1700, Cleveland, Ohio 44114 (US). claims and to be republished in the event of receipt of (81) Designated States (unless otherwise indicated, for every amendments (Rule 48.2(h)) kind of national protection available): AE, AG, AL, AM, _ with sequence listing part of description (Rule 5.2(a)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (54) Title: TDP-43 MITOCHONDRIAL — DISEASE 1 — 1 GC Ir...' 11 IN IN 11 IN Il N (57) : A method of treating effective amount of a TDP-43 LOCALIZATION INHIBITOR FOR THE TREATMENT OF NEURODEGENERATWE Cnntro , t a d: Centro . , c i s 40 Oiii D!Staret, , ) F—IDP-43 Tern* Figs. 1A a neurodegenerative disease in a subject includes administering to the subject a therapeutically mitochondrial localization inhibitor. O
SG11201808829VA 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease SG11201808829VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319580P 2016-04-07 2016-04-07
US201662328484P 2016-04-27 2016-04-27
PCT/US2017/026675 WO2017177178A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
SG11201808829VA true SG11201808829VA (en) 2018-11-29

Family

ID=60000683

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808829VA SG11201808829VA (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Country Status (9)

Country Link
US (2) US11124553B2 (en)
EP (1) EP3440094B1 (en)
JP (1) JP2019513752A (en)
KR (1) KR20180132807A (en)
CN (1) CN109563130A (en)
AU (1) AU2017248353A1 (en)
CA (1) CA3020344A1 (en)
SG (1) SG11201808829VA (en)
WO (1) WO2017177178A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906949B2 (en) * 2017-06-28 2021-02-02 The Cleveland Clinic Foundation Methods of treating spinal cord injury using a chondroitin sulfate proteoglycan (CSPG) reduction peptide (CRP) comprising a cell membrane penetrating domain, a CSPG binding domain, and a lysosome targeting domain
CN113683703B (en) * 2020-05-18 2023-08-15 中国人民解放军陆军军医大学第二附属医院 hTERT target and application thereof
WO2021247893A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroaromatic amide compounds and uses thereof
CN114057858B (en) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 Polypeptides having a disaggregating effect on protein aggregation causing neurodegenerative and neurodegenerative diseases
KR102488166B1 (en) 2020-09-24 2023-01-13 재단법인대구경북과학기술원 Use of HDAC6 for preventing or treating TDP-43 proteinopathy
JP6961278B1 (en) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 Methods and Devices for Measuring TDP-43 in Biological Samples
CN113450336B (en) * 2021-07-01 2022-10-25 维柯基科技(上海)有限公司 Processing method and device of porous fluorescent microarray image, computer equipment and computer readable storage medium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
JPH09500783A (en) 1993-05-21 1997-01-28 ターゲッティッド ジェネティクス コーポレイション Bifunctional selective fusion gene based on cytosine deaminase (CD) gene
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723824D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Cytostatic agents
WO2002010201A2 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
CN101287988B (en) * 2005-07-01 2012-10-10 阿波维塔公司 Methods and compositions for diagnosis and treatment of influenza
EP2097090B1 (en) 2006-12-06 2014-10-29 Thomas Jefferson University Peptide and treatment for hiv-1 infection
CA2713871C (en) * 2008-02-01 2018-05-22 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9926353B2 (en) * 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
EP2821504A4 (en) 2012-02-28 2016-02-17 Univ Tokyo Nat Univ Corp Method for designating disease relating to amount of tdp-43 existing in cells
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)

Also Published As

Publication number Publication date
US11124553B2 (en) 2021-09-21
EP3440094B1 (en) 2021-02-17
KR20180132807A (en) 2018-12-12
EP3440094A4 (en) 2019-03-20
EP3440094A1 (en) 2019-02-13
AU2017248353A1 (en) 2018-10-25
CA3020344A1 (en) 2017-10-12
CN109563130A (en) 2019-04-02
US20220220173A1 (en) 2022-07-14
WO2017177178A1 (en) 2017-10-12
JP2019513752A (en) 2019-05-30
US20190211070A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
SG11201808829VA (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908391XA (en) Methods for modulating an immune response
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201807785VA (en) Neuroactive steroids, compositions, and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909949XA (en) Targeted immunotolerance
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201805579SA (en) Recombinant igg fc multimers
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201907490XA (en) Non-human animal models of retinoschisis
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201909882SA (en) Targeted neoepitope vectors and methods therefor